Summary The tumour-suppressor gene TP53 is frequently mutated in breast tumours, and the majority of the mutations are clustered within the core domain, the region involved in DNA binding. We searched for alterations in this central domain of the TP53 gene in 222 human breast cancer specimens using polymerase chain reaction-single-strand conformation analysis (PCR-SSCA) followed by sequencing. TP53 gene mutations were observed in 66 tumours (31 %), including three tumours that contain two mutations. Fifty-four (78%) of these mutations were missense point mutations, one was a nonsense mutation and four were deletions and/or insertions causing disruption of the protein reading frame, whereas four mutations were either silent or a polymorphism (at codon 213; n = 6). Interestingly, the majority of missense mutations were observed at codon 248. The outcome has been related with patient and tumour characteristics, and with prognosis in 177 patients who were eligible for analysis of both relapse-free and overall survival (median survival for patients alive was 115 months). There was no significant association between the frequency of TP53 mutations and menopausal or nodal status, or tumour size. In a Cox univariate analysis, TP53 gene mutation was significantly associated with poor relapse-free survival (RFS: P = 0.02) but not with overall survival (OS: P = 0.07). In a Cox multivariate analysis, including classical prognostic factors, TP53 gene mutation independently predicted poor RFS and OS (RHR = 1.8 and 1.6 respectively). Unexpectedly, the median relapse-free survival of patients with a polymorphism at codon 213 or with a silent mutation was shorter (median 11 months) than the median relapse-free survival of patients with or without a TP53 gene mutation (median 34 or 48 months respectively). In an exploratory subset analysis, mutations in codons that directly contact DNA were related with the poorest relapse-free (P < 0.05) and overall survival (P < 0.02). These data imply that in the analysis of the prognostic value of TP53, the type of mutation and its biological function should be considered.
The tumour-suppressor gene TP53 (also known as p53) plays a key role in cell cycle regulation, gene transcription, genomic stability, DNA repair, senescence and apoptosis (reviewed in Haffner and Oren, 1995; Kinzler and Vogelstein, 1996; Velculescu and El-Deiry, 1996; Harris, 1996a) . Inactivation of wild-type functions of TP53 by either mutation of the gene, nuclear exclusion, interaction of its protein product with either cellular proteins (for example MDM2) or oncogene products of DNA tumour viruses can lead to cancer (Levine et al, 1991) . Point mutation is the most common event and as this is often accompanied by deletion of the second allele, all wild-type TP53 activity will be eliminated.
The structure-function relationship of the TP53 protein provided a basis for understanding how TP53 mutations might inactivate its normal cell function. The central portion of TP53 consists of three loops involved in DNA binding (Cho et al, 1994) . Most mutations are clustered within the core domain (residues 102-292) and mutations are particularly common in the four conserved regions located in this core domain (Cariello et al, 1994; Greenblatt et al, 1994; Harris, 1996b) . In general, these mutations are missense (Cariello et al, 1994) , resulting in a defective or conformationally altered non-functional protein (Harris, 1996b) . Up to 20% of the mutations, however, have been reported outside exons 5-8, and these are predominantly of the 'null type' (Bergh et al, 1995; Hartmann et al, 1995) . There are two functional classes of mutations, of which class I affects residues that directly contact DNA (for example hotspots Arg-248 and Arg-273) and of which class II affects residues that have a critical role in stabilizing the structural integrity of the domain (for example hotspot Arg-175) (Prives, 1994) .
TP53 gene mutation is the most common single gene alteration in breast cancer and, depending on the method of detection, the frequencies of TP53 mutations reported in invasive breast cancer range from 12% to 46% (Andersen and B0rresen, 1995) . The transitions of the major CpG dinucleotide hotspots at codons 175, 248 and 273 are the most prevalent (Cariello et al, 1994; Greenblatt et al, 1994; Hartmann et al, 1997) . In general, TP53 gene alterations have been associated with worse prognosis of breast cancer patients. However, various mutations can alter the TP53 protein distinctly, which may lead to different biological characteristics and tumorigenic potential (Cho et al, 1994; Friend, 1994) . Analysis of these various mutations allows us to focus attention on the biological significance of particular mutations, which may abet selection of those residues that could be of predictive value in breast cancer.
In the present study on breast carcinoma samples, both type and location of TP53 gene alterations were studied. The outcome, by function of affected codons and regions, was related with patient and tumour characteristics and with (relapse-free) survival. TP53 mutations that contact DNA predict poor outcome 1131 PATIENTS AND METHODS Patients and tumour samples TP53 gene alterations were studied in a series of 222 female breast tumours. Of the patients, 177 were eligible for evaluation of relapse-free and overall survival according to the strict criteria described previously . The 45 patients who were excluded from the analyses of (relapse-free) survival involved 37 for whom tumour characteristics were unknown and no records were available and eight for whom follow-up was not detailed enough. Patients underwent surgical tumour removal (124 mastectomy, 53 lumpectomy) between 1978 and 1990 . Radiotherapy on the breast or thoracic wall was given to 89 patients, of the axilla to 81 patients and of other lymph node areas (supraclavicular and/or parastemal) to 143 patients. The median age of these patients was 59 years (range, 28-82 years), 33% were premenopausal, 36% had no involved lymph nodes, and the majority of the patients had tumours < 5 cm.
Of the node-positive patients, 39 patients (35%) received systemic adjuvant therapy (30 patients received CMF; seven patients tamoxifen and two patients a combination of hormonal therapy and chemotherapy). One node-negative patient received systemic adjuvant therapy. These and further details of the patients, with a medium follow-up of patients alive of 115 months (range, 47-183 months), are given in Table 1 . One-hundred and eight patients (61%) experienced a relapse and 106 patients (60%) died during follow-up of this study.
DNA isolation and sequence analysis
Breast tumour specimens, stored in liquid nitrogen, were pulverized and homogenized in phosphate buffer according to the procedures recommended by the EORTC (EORTC Breast Cancer Cooperative Group, 1973) . High-molecular-weight chromosomal DNA was isolated from an aliquot of the total tissue homogenate as described previously (Berns et al, 1992) . Exons 5 through 8 of the TP53 gene were analysed by polymerase chain reaction (PCR) driven single-strand conformation analysis (PCR-SSCA), as described previously (Berns et al, 1996) . The mammary tumour cell line EVSA-T was included in the assay as a positive control for the neutral polymorphism at codon 213 (exon 6), which occurs in 3-10% of the normal population (Carbone et al, 1991) . Because of possible errors that may accumulate in the initial PCR step, samples showing an altered electrophoretic mobility of singlestranded nucleic acids were analysed again with an independent PCR product. A third PCR product was sequenced (Ampli-Cycle sequencing kit, Perklin Elmer, Branchbury, NJ, USA) with 5-prime 33P end-labelled primers. The DNA sequence was determined by separation of the terminated products on a 6% polyacrylamide gel containing 8 M urea, followed by autoradiography. The naturally occurring restriction sites of HaeII, TaqI and MspI were used to verify mutations in codons 175 (exon 5), 213 (A-*G polymorphism in exon 6) and 248 (exon 7) respectively.
Luminometric immunoassay
The TP53 protein levels were measured in 151 breast tumour cytosols, which were available from the cytosol bank, using a quantitative luminometric immunoassay (LIA; AB Sangtec Medical, Bromma, Sweden), described previously by us (De Witte (see Table 1 ). Sixty-six tumour samples were successfully sequenced and 69 TP53 gene mutations were found in these 66 tumour samples (see Table 1 and Figure 1 (Table 2 ). The median RFS in the six patients with a mutation at codon 213 (neutral polymorphism) or a silent mutation (in exon 7) was shorter (median RFS = 11; range 7-107 months) than the RFS of the 47 patients with a mutation (median RFS = 34; range 3-160 months) and with the median RFS of 124 patients with wild-type TP53 (median RFS = 48; range 2-183 months).
In an exploratory analysis the TP53 gene mutations were stratified according to type of mutation, for example evolutionarily conserved regions, zinc-binding domains L2 (residues 163-195) and L3 (residues 236-251) of the protein, by residues that directly British Journal of Cancer (1998) 77(7) . bSite, L2/L3, loop 2 or loop 3; psr, protein stabilizing region; Zn, zinc-binding domain; DNA, direct contact with DNA. Del/d, deletion; insfi, insertion; n, nonsense; *position of base. CLIA, luminometric immunoassay (see Patients and methods). dT tumour size (1, < 2 cm; 2, 2-5 cm; 3/4, > 5 cm); N, nodal status (0, node negative; 1, node positive; x, unknown). eDFS, disease-free survival in months. 'Site of relapse: SCCI, distant nodes; META, distant metastasis; LRR, local regional relapse; D-BRCA, dead without evidence of recurrent disease. Only patients with complete tumour characteristics available were included in this Figure 1 and Results.
contact DNA (Table 3 ) and by occurrence of silent mutations. Cox univariate analysis, at 5 years, showed that both the relapse-free and overall survival of patients with TP53 mutations in either the conserved regions, within L2 and L3, or the codons that directly contact DNA is significantly worse (relative hazard rate (RHR) for RFS: 1.9, 2.0, 2.7 and 4.1 respectively; see Table 3 ) than those patients without mutations (WT, wild type), or with mutations in codons that are not conserved or are outside L2 and L3. Actuarial relapse-free and overall survival curves stratified by TP53 status revealed that the TP53 gene mutation was significantly (P = 0.02) associated with an increased risk of relapse with a RHR of 1.6 [95% confidence interval (CI): 1.1-2.4], but not with the rate of death [P = 0.07; RHR = 1.5 (CI = 0.97-2.2), shown in Figure 2A and B]. When stratified as the function of type of TP53 mutation, only mutations at residues that directly contact DNA retained significance (RFS: P < 0.05 and OS: P < 0.02, respectively, shown in Figure 2C and D) .
In a multivariate Cox regression analysis, which included age, menopausal status, lymph node status, tumour size, steroid hormone receptor status and c-MYC amplification, TP53 gene mutation independently predicts poor RFS and OS with relative hazard rates of 1.8 (P < 0.01) and 1.6 (P = 0.04) respectively.
DISCUSSION
The present prevalence of TP53 mutations is in the range of the overall rate of TP53 mutations of 15-71% (mean 25%; examined in 1452 breast tumour samples worldwide, by SSCA of exon 5-8, and reviewed by Hartmann et al, 1997) . Evaluation of only exons 5 through 8 may, however, underestimate the overall prevalence of TP53 mutations by 10-20% (Bergh et al, 1995; Hartmann et al, 1995) . The mutations observed in this study resided mainly (41%) in exon 7. This high incidence is in accordance with the study of Anderson et al (1993) who also described a predominance of mutations in exon 7. The mutational 'hotspots' described in breast cancer (Greenblatt et al, 1994) , i.e. codons Arg-175, Arg-248 and Arg-273 accounted for 3%, 17% and 7%, respectively, in this study.
This differs from the prevalence of 6%, 7%, and 7%, respectively, summarized in the database established by Cariello et al (1994) on TP53 gene mutations (n = 365) in human primary breast tumours.
Interestingly, B0rresen et al (1995) also showed a relatively lower frequency (3%) of mutations in codon 175 and this could imply a lower prevalence of codon 175 mutations in European women. When stratifying the mutations according to the evolutionarily conserved regions or functional domains, we observed that 41 out of 59 mutations (69%) were restrained to the conserved regions, which is in concordance with the percentage of mutations (73%) in this region summarized by Cariello et al (1994) . Bergh et al (1995) , who studied mainly tumours from node-negative patients, observed a smaller number of mutations in these conserved regions, i.e. 30 out of 65 (46%). In our smaller number of nodenegative patients 13 out of 21 mutations were in the conserved regions (62%). Twenty-five mutations (42%) in this study were within the structural regions L2 and L3, which is in accordance with data observed by B0rresen et al (1995) .
As expected, the median TP53 level of tumours with missense mutations was higher (eightfold) than levels of tumours with a silent mutation or without a gene alteration, but also with four tumours with deletions/insertions. This last result shows that low levels of TP53 measured by LIA, and probably also by immunohistochemistry, are not always indicative of a normal TP53 gene status and the data should be interpreted with care.
An unexpected finding was that the median RFS in the six patients with a neutral polymorphism at codon 213 or a silent mutation was shorter (median RFS = 11 months) than the RFS of the 47 patients with a mutation (median RFS = 34 months) and with the median RFS of 124 patients with wild-type TP53 (median RFS = 48 months). Shiao et al (1995) also reported that two patients with the A-*G transition in codon 213 experienced a very poor survival, but more studies on this silent third base mutation in Arg-213 will be needed to clarify these observations. We also observed that the different TP53 gene mutations in primary breast cancer could be related to differences in (relapse-free) survival, for example our study shows that mutations that directly contact DNA are related with a poor (relapse-free) survival of breast cancer patients. This does not agree with data from B0rresen et al (1995) . These authors reported that, in a multicentre study, patients with TP53 mutations in the zinc-binding domains (L2 and L3) had a poor prognosis. One possible explanation for the observed difference could be the shorter follow-up time in their study (median: 40 months vs 115 months in this study). In conclusion, the analysis of type and location of TP53 alterations can be used to select residues British Journal of Cancer (1998) that could be of prognostic value. If these data are confirmed by other investigators in larger studies, the use of artificially or naturally created restriction sites or allele-specific oligo techniques can facilitate the detection of these DNA contact residues.
